» Articles » PMID: 25711194

Radical Prostatectomy or External Beam Radiation Therapy Vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2015 Feb 26
PMID 25711194
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We assessed survival after radical prostatectomy, intensity modulated radiation therapy or conformal radiation therapy vs no local therapy for metastatic prostate cancer adjusting for patient comorbidity, androgen deprivation therapy and other factors.

Materials And Methods: We identified men 66 years old or older with metastatic prostate cancer treated with radical prostatectomy, intensity modulated radiation therapy, conformal radiation therapy or no local therapy in the SEER-Medicare linked database from 2004 to 2009. Multivariable Cox proportional hazards models before and after inverse propensity score weighting were used to assess all cause and prostate cancer specific mortality. Competing risk regression analysis was done to assess prostate cancer specific mortality.

Results: Of 4,069 men with metastatic prostate cancer radical prostatectomy in 47, intensity modulated radiation therapy in 88 and conformal radiation therapy in 107 were selected as local therapy vs no local therapy in 3,827. Radical prostatectomy was associated with a 52% decrease (HR 0.48, 95% CI 0.27-0.85) in the risk of prostate cancer specific mortality after adjusting for sociodemographics, primary tumor characteristics, comorbidity, androgen deprivation therapy and bone radiation within 6 months of diagnosis. Intensity modulated radiation therapy was associated with a 62% decrease (HR 0.38, 95% CI 0.24-0.61) in the risk of prostate specific cancer specific mortality. Conformal radiation therapy was not associated with improved survival compared to no local therapy. Propensity score weighting yielded comparable results. Competing risk analysis revealed a 42% and 57% decrease (SHR 0.58, 95% CI 0.35-0.95 and SHR 0.43, 95% CI 0.27-0.68, respectively) in the risk of prostate cancer specific mortality for radical prostatectomy and intensity modulated radiation therapy.

Conclusions: Local therapy with radical prostatectomy and intensity modulated radiation therapy but not with conformal radiation therapy was associated with a survival benefit in men with metastatic prostate cancer. This finding warrants prospective evaluation in clinical trials.

Citing Articles

Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment.

Schutz V, Nessler C, Duensing A, Zschabitz S, Jager D, Debus J Front Oncol. 2024; 14:1475914.

PMID: 39720562 PMC: 11666478. DOI: 10.3389/fonc.2024.1475914.


Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.

Wang T, Wang X, Ding G, Liu H, Ma X, Ma J Br J Cancer. 2024; 131(8):1363-1377.

PMID: 39223303 PMC: 11479264. DOI: 10.1038/s41416-024-02823-3.


A systematic review of cytoreductive prostatectomy outcomes and complications in oligometastatic disease.

Morozov A, Chuvalov L, Taratkin M, Enikeev M, Rapoport L, Singla N Asian J Urol. 2024; 11(2):208-220.

PMID: 38680575 PMC: 11053306. DOI: 10.1016/j.ajur.2022.03.017.


Biochemical outcome in metastatic prostate cancer patients following prostate-directed radiotherapy.

Ayoub H, Elsayed F, Zamzam M, Hassanin I, Elsemary E Ecancermedicalscience. 2024; 18:1686.

PMID: 38566761 PMC: 10984844. DOI: 10.3332/ecancer.2024.1686.


Minimally invasive cytoreductive radical prostatectomy, exploring the safety and feasibility of a single-port or multi-port robotic platform.

Lama D, Thomas K, Vernez S, Okunowo O, Lau C, Yuh B BMC Urol. 2024; 24(1):72.

PMID: 38532371 PMC: 10964602. DOI: 10.1186/s12894-024-01463-2.


References
1.
Hu J, Gu X, Lipsitz S, Barry M, DAmico A, Weinberg A . Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009; 302(14):1557-64. DOI: 10.1001/jama.2009.1451. View

2.
Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway C . Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011; 29(18):2574-81. PMC: 3138635. DOI: 10.1200/JCO.2010.33.2999. View

3.
Roberts C, Jang T, Shao Y, Kabadi S, Moore D, Lu-Yao G . Treatment profile and complications associated with cryotherapy for localized prostate cancer: a population-based study. Prostate Cancer Prostatic Dis. 2011; 14(4):313-9. PMC: 3151329. DOI: 10.1038/pcan.2011.17. View

4.
Fleming S, Hamilton A, Sabatino S, Kimmick G, Wu X, Owen J . Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review. Med Care. 2012; 52(9):e58-64. PMC: 5874805. DOI: 10.1097/MLR.0b013e318277eba5. View

5.
Stattin P, Loeb S . "To measure is to know. If you cannot measure it, you cannot improve it": statistical modeling cannot compensate for unmeasured bias. Eur Urol. 2013; 65(4):701-3. DOI: 10.1016/j.eururo.2013.06.037. View